The article discusses the revisions made to the World Medical Association's Declaration of Helsinki and the ethics of clinical trials. The provision of the drug company to maintain supply of the drug after the trial has ended is analysed. Government policy on clinical trials, role of pharmaceutical companies and human subjects as volunteers is discussed.